About Prometheus Biosciences
Prometheus Biosciences is a Healthcare company based in San Diego (United States) founded in 2016 by Stephan Targan, and was acquired by Merck in April 2023. Drugs for gastrointestinal diseases are developed using clinical biobanks. Prometheus Biosciences has raised $130 million across 1 funding round from investors including Merck, Nestlé and Cedars Sinai. Its focus areas include Life Sciences, Gastroenterology, Drugs and Bowel Disorders. Its competitors include Aclaris Therapeutics, Protagonist Therapeutics and Kanvas Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Prometheus Biosciences was founded in 2016 in San Diego, United States, within the biotechnology sector. Treatments for gastrointestinal diseases, especially bowel-related conditions, are developed through a clinical biobank that includes medical records. Targets for biomarker-defined subclinical GI phenotypes are identified using this resource. Pipeline products are advanced through clinical trial phases to address patient needs in this area.
- Headquarters San Diego, United States
- Founders Stephan Targan
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website prometheusbiosciences.com
- Social LinkedIn X
- Acquired by Merck (Apr 2023)
Funding Insights of Prometheus Biosciences
Prometheus Biosciences has successfully raised a total of $130M through 1 strategic funding round. The most recent funding activity was a Series D round of $130 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130M
- Total Rounds 1
- Last Round Series D — $130M
- First Round $130M
(Nov 2020)
- Investors Count 10
All 1 funding rounds of Prometheus Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $130M | Series D | – | Eventide Funds, RTW Investments |
11 investors in total: 11 institutional.
Investors in Prometheus Biosciences
Prometheus Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Nestlé and Cedars Sinai.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early-stage startups are invested in by sector-agnostic VC fund. | irvinginvestors.com | New York, United States | ||
AGI Partners is engaged in partnering with entrepreneurs for growth. | agi-llc.com | Lewes, United States | ||
Eventide Mutual Funds is managed by Eventide Asset Management, offering investment solutions. | eventidefunds.com | Boston, United States | ||
Sourcing and deploying capital for real estate investments and developments. | cormorant-capital.com | New York, United States | ||
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States | |
Manages alternative investments through equity, systematic, macro, and private strategies worldwide. | 2014 | point72.com | Stamford, United States | |
Chain of multispeciality hospital | 1902 | cedars-sinai.org | United States | |
Multi-category food and beverage products are produced and distributed globally. | 1866 | nestle.com | Vevey, Switzerland |
Investor details for Prometheus Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Prometheus Biosciences
1249 people are tracked at Prometheus Biosciences (846 in leadership, 12 in board & advisors, 391 in team).
| Name | Role | Group |
|---|---|---|
Stephan Targan | Co-Founder | Leadership |
Jacob Bordens | Senior Director, Enterprise Architecture | Leadership |
Kelley Brna | Vice President Operations | Leadership |
Robert Tynebor | Director | Leadership |
Jerry Timmons | Retired Associate Director Of Operations | Leadership |
Sebastian S. | Director | Leadership |
Dave Williams | EVP, Chief Information & Digital Officer | Leadership |
Hardik Chandasana | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
My Mansueto | Director | Leadership |
Edina Avdic | Associate Director-regulatory Affairs-global Labeling | Leadership |
Manshi Patel | Associate Director- Global Microbial Quality Sterility Assurance | Leadership |
Sany Hoxha | Director, Oncology Translational Science And Clinical Biomarkers | Leadership |
Ashley Wivel | Vice President, Head Of Clinical Safety And Risk Management | Leadership |
Naveed Shaik | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
Allison Shaner | Chief Of Staff, HR Manufacturing | Leadership |
Brandon Koffel | Associate Director Discovery Sourcing & Procurement - Global Clinical Supply & Analytical Labs | Leadership |
Andrea Lorena Buitrago Lozano | Associate Director, Lead Study Manager | Leadership |
Aatosh Chauhan | Executive Director, External Manufacturing Strategy & Operations At Merck | Leadership |
Renata Eiras | Executive Director, Distinguished Scientist, PDT Lead | Leadership |
Gina M. Gualtiere Mshs | Associate Director Clinical Quality Operations | Leadership |
1229 more people are available in the full profile.
Complete people profiles for Prometheus Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Prometheus Biosciences
4 dated milestones of Prometheus Biosciences across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Prometheus Biosciences is founded.
- Funding First funding round of $130.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Merck.
Competitors of Prometheus Biosciences
Prometheus Biosciences has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Protagonist Therapeutics and Kanvas Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| protagonist-inc.com | 2001 | Milpitas, United States | $67M | 112 | Oral peptide therapeutics are developed for gastrointestinal diseases. | |
| kanvasbio.com | 2021 | Ithaca, United States | $24.28M | Imaging solutions for microbial research and infectious diseases are provided. |
Detailed competitors of Prometheus Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Prometheus Biosciences (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Prometheus Biosciences
Complete news archive for Prometheus Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Prometheus Biosciences
Prometheus Biosciences was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Prometheus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Prometheus Biosciences is a funded company, having raised a total of $130M across 1 funding round to date. The company's 1st funding round was a Series D of $130M, raised on Nov 2020.
Prometheus Biosciences was founded in 2016 in San Diego, United States, within the biotechnology sector. Treatments for gastrointestinal diseases, especially bowel-related conditions, are developed through a clinical biobank that includes medical records. Targets for biomarker-defined subclinical GI phenotypes are identified using this resource. Pipeline products are advanced through clinical trial phases to address patient needs in this area.
Prometheus Biosciences's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Kanvas Biosciences.
Prometheus Biosciences has 11 investors. Key investors include Merck, Nestlé, Cedars Sinai, TD Securities, and RTW Investments.
Yes. Prometheus Biosciences was acquired by Merck in April 2023.